Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4874119 | 0.98 | INPP5A (0.47) | NCF1INPP5AGNAI3GNAO1GNAI1 | |
| SCHEMBL9699111 | 0.89 | INPP5A (0.42) | NCF1INPP5AGNAI3GNAO1GNAI1 | |
| SCHEMBL29271261 | 0.89 | INPP5A (0.42) | NCF1INPP5AGNAI3GNAO1GNAI1 | |
| SCHEMBL29252437 | 0.85 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL12439743 | 0.80 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL12593551 | 0.79 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL20893419 | 0.79 | SMN1; SMN2 (0.46) | INPP5ASMYD3HRH3 | |
| SCHEMBL19734284 | 0.78 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL20744331 | 0.78 | NCF1 (0.52) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL9099973 | 0.78 | INPP5A (0.62) | INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969934-A | Pyrimido aromatic ring compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-2766354-B1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-05-18 | — | — | EP | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| EP-1953160-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | CRHR1, CRHR2, HRH4 | NCF1 1169/4885INPP5A 1055/4885GNAI3 1219/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | NCF1 1076/4885INPP5A 1145/4885GNAI3 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.